Síndrome hepatorrenal

Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.Texto completo  Resumen

Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020 Sep 14;370:m2687.Texto completo  Resumen

European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-60.Texto completo  Resumen

European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417.Texto completo  Resumen

1. Dagher L, Moore K. The hepatorenal syndrome. Gut. 2001 Nov;49(5):729-37.Texto completo  Resumen

2. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021 Aug;74(2):1014-48.Texto completo  Resumen

3. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996 Jan;23(1):164-76.Texto completo  Resumen

4. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015 Apr;62(4):968-74.Texto completo  Resumen

5. Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020 Sep 14;370:m2687.Texto completo  Resumen

6. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol. 2011 Aug;55(2):315-21. Resumen

7. Martín-Llahí M, Pépin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008 May;134(5):1352-9.Texto completo  Resumen

8. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-60.Texto completo  Resumen

9. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993 Jul;105(1):229-36.Texto completo  Resumen

10. Patidar KR, Belcher JM, Regner KR, et al. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. J Hepatol. 2023 Dec;79(6):1408-17. Resumen

11. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008 Dec;48(6):2064-77.Texto completo  Resumen

12. Nadim MK, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis. N Engl J Med. 2023 Feb 23;388(8):733-45. Resumen

13. Cárdenas A, Arroyo V. Hepatorenal syndrome. Ann Hepatol. 2003 Jan-Mar;2(1):23-9.Texto completo  Resumen

14. Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019 Oct;71(4):811-22. Resumen

15. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417.Texto completo  Resumen

16. Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007 Dec;46(6):1872-82.Texto completo  Resumen

17. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008;48 Suppl 1:S93-103.Texto completo  Resumen

18. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007 Sep;56(9):1310-8.Texto completo  Resumen

19. Gines P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol. 1999 Aug;10(8):1833-9.Texto completo  Resumen

20. Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet. 2003 Nov 29;362(9398):1819-27. Resumen

21. Flamm SL, Wong F, Ahn J, et al. AGA clinical practice update on the evaluation and management of acute kidney injury in patients with cirrhosis: expert review. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2707-16.Texto completo  Resumen

22. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999 Aug 5;341(6):403-9.Texto completo  Resumen

23. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology. 2001 Dec;34(6):1242-51.Texto completo  Resumen

24. Castro-Narro G, Moctezuma-Velázquez C, Male-Velázquez R, et al. Position statement on the use of albumin in liver cirrhosis. Ann Hepatol. 2022 Jul-Aug;27(4):100708.Texto completo  Resumen

25. Bai Z, Méndez-Sánchez N, Romeiro FG, et al. Use of albumin infusion for cirrhosis-related complications: an international position statement. JHEP Rep. 2023 May 5;5(8):100785.Texto completo  Resumen

26. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9.Texto completo  Resumen

27. Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994 Jan 24;154(2):201-5. Resumen

28. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis. 2003 Feb;41(2):269-78. Resumen

29. Arnold J, Avila E, Idalsoaga F, et al. Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation. eGastroenterology. 2023 Nov 23;1:e100009.Texto completo

30. Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014 Jun;146(7):1680-90.e1.Texto completo  Resumen

31. Fabrizi F, Dixit V, Messa P, et al. Terlipressin for hepatorenal syndrome: a meta-analysis of randomized trials. Int J Artif Organs. 2009;32:133-140. Resumen

32. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24:935-944.Texto completo  Resumen

33. Singal AK, Palmer G, Melick L, et al. Vasoconstrictor therapy for acute kidney injury hepatorenal syndrome: a meta-analysis of randomized studies. Gastro Hep Adv. 2023 Jan 18;2(4):455-64.Texto completo  Resumen

34. Sridharan K, Sivaramakrishnan G. Vasoactive agents for hepatorenal syndrome: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. J Gen Intern Med. 2018 Jan;33(1):97-102.Texto completo  Resumen

35. Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev. 2019 Sep 12;(9):CD013103.Texto completo  Resumen

36. Israelsen M, Krag A, Allegretti AS, et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Database Syst Rev. 2017 Sep 27;(9):CD011532.Texto completo  Resumen

37. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021 Mar 4;384(9):818-28.Texto completo  Resumen

38. Hiremath SB, Srinivas LD. Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: a meta-analysis. Indian J Pharmacol. 2013 Jan-Feb;45(1):54-60.Texto completo  Resumen

39. European Medicines Agency. Terlipressin-containing medicinal products indicated in the treatment of hepatorenal syndrome. Sep 2022 [internet publication].Texto completo

40. Medicines and Healthcare products Regulatory Agency. Terlipressin: new recommendations to reduce risks of respiratory failure and septic shock in patients with type 1 hepatorenal syndrome. Mar 2023 [internet publication].​Texto completo

41. US Food and Drug Administration. FDA approves treatment to improve kidney function in adults with hepatorenal syndrome. Sep 2022 [internet publication].Texto completo

42. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015 Aug;62(2):567-74. Resumen

43. Wong LP, Blackley MP, Andreoni KA, et al. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int. 2005 Jul;68(1):362-70.Texto completo  Resumen

44. Allegretti AS, Parada XV, Eneanya ND, et al. Prognosis of patients with cirrhosis and AKI who initiate RRT. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):16-25.Texto completo  Resumen

45. Stutchfield BM, Simpson K, Wigmore SJ. Systematic review and meta-analysis of survival following extracorporeal liver support. Br J Surg. 2011 May;98(5):623-31. Resumen

46. Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009 Apr;43(4):692-9. Resumen

47. Bagger Y, Ravis WR, Harris G, et al. OCE-205, a novel, selective vasopressin receptor mixed agonist-antagonist: safety, tolerability, and pharmacokinetics/pharmacodynamics from a phase 1 study in healthy volunteers. Clin Drug Investig. 2023 Sep;43(9):709-17.Texto completo  Resumen

48. ClinicalTrials.gov. A study of OCE-205 in participants with cirrhosis with ascites who developed hepatorenal syndrome-acute kidney injury. ClinicalTrials.gov Identifier: NCT05309200. Dec 2023 [internet publication].Texto completo

49. Guevara M, Ginès P. Hepatorenal syndrome. Dig Dis. 2005;23(1):47-55.Texto completo  Resumen

50. Thomson MJ, Taylor A, Sharma P, et al. Limited progress in hepatorenal syndrome (HRS) reversal and survival 2002-2018: a systematic review and meta-analysis. Dig Dis Sci. 2020 May;65(5):1539-48.Texto completo  Resumen

51. Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385-1394. Resumen

52. Boyer TD, Sanyal AJ, Garcia-Tsao G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011 Nov;17(11):1328-32.Texto completo  Resumen

53. Utako P, Emyoo T, Anothaisintawee T, et al. Clinical outcomes after liver transplantation for hepatorenal syndrome: a systematic review and meta-analysis. Biomed Res Int. 2018 May 24:2018:5362810.Texto completo  Resumen